JP6300042B2 - 癌の処置に使用するための化合物の製造方法 - Google Patents

癌の処置に使用するための化合物の製造方法 Download PDF

Info

Publication number
JP6300042B2
JP6300042B2 JP2015536988A JP2015536988A JP6300042B2 JP 6300042 B2 JP6300042 B2 JP 6300042B2 JP 2015536988 A JP2015536988 A JP 2015536988A JP 2015536988 A JP2015536988 A JP 2015536988A JP 6300042 B2 JP6300042 B2 JP 6300042B2
Authority
JP
Japan
Prior art keywords
compound
formula
group
preparation
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015536988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533175A (ja
Inventor
スリラム ナガナサン，
スリラム ナガナサン，
ネイサン グズ，
ネイサン グズ，
マシュー ファイファー，
マシュー ファイファー，
シー． グレゴリー ソウェル，
シー． グレゴリー ソウェル，
トレイシー ボスティック，
トレイシー ボスティック，
ジェイソン ヤン，
ジェイソン ヤン，
アミット スリバスタバ，
アミット スリバスタバ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2015533175A publication Critical patent/JP2015533175A/ja
Application granted granted Critical
Publication of JP6300042B2 publication Critical patent/JP6300042B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015536988A 2012-10-12 2013-10-14 癌の処置に使用するための化合物の製造方法 Active JP6300042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
US61/713,104 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017234208A Division JP2018052973A (ja) 2012-10-12 2017-12-06 癌の処置に使用するための化合物の製造方法

Publications (2)

Publication Number Publication Date
JP2015533175A JP2015533175A (ja) 2015-11-19
JP6300042B2 true JP6300042B2 (ja) 2018-03-28

Family

ID=49474740

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015536988A Active JP6300042B2 (ja) 2012-10-12 2013-10-14 癌の処置に使用するための化合物の製造方法
JP2017234208A Withdrawn JP2018052973A (ja) 2012-10-12 2017-12-06 癌の処置に使用するための化合物の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017234208A Withdrawn JP2018052973A (ja) 2012-10-12 2017-12-06 癌の処置に使用するための化合物の製造方法

Country Status (31)

Country Link
US (4) US9771347B2 (https=)
EP (1) EP2909188B1 (https=)
JP (2) JP6300042B2 (https=)
KR (1) KR102204520B1 (https=)
CN (2) CN108948043B (https=)
AU (1) AU2013328929B2 (https=)
BR (1) BR112015008113B1 (https=)
CA (1) CA2889466C (https=)
CL (1) CL2015000926A1 (https=)
CR (2) CR20200237A (https=)
EA (1) EA030613B1 (https=)
ES (1) ES2671502T3 (https=)
GE (1) GEP201706690B (https=)
HK (1) HK1213567A1 (https=)
HR (1) HRP20180670T1 (https=)
IL (1) IL238116B (https=)
IN (1) IN2015DN03928A (https=)
MA (1) MA38085B1 (https=)
MX (2) MX372708B (https=)
MY (1) MY186549A (https=)
NZ (1) NZ706723A (https=)
PE (3) PE20151494A1 (https=)
PH (1) PH12015500785A1 (https=)
PL (1) PL2909188T3 (https=)
SA (1) SA515360271B1 (https=)
SG (1) SG11201502795VA (https=)
SI (1) SI2909188T1 (https=)
TR (1) TR201807861T4 (https=)
UA (1) UA115455C2 (https=)
WO (1) WO2014059422A1 (https=)
ZA (1) ZA201502349B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38085B1 (fr) 2012-10-12 2018-11-30 Exelixis Inc Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
CA2987912C (en) 2015-06-30 2023-01-24 Genentech, Inc. Immediate-release tablets containing a drug and processes for forming the tablets
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
AU2017311585A1 (en) 2016-08-12 2019-02-28 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
AU2017335839A1 (en) 2016-09-29 2019-04-18 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
JP2024509269A (ja) 2021-03-09 2024-02-29 ジェネンテック， インコーポレイテッド 脳がんの治療における使用のためのベルバラフェニブ
EP4319749A1 (en) 2021-04-06 2024-02-14 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
CA2186947A1 (en) 1994-04-01 1995-10-12 Kazuo Ueda Oxime derivative and bactericide containing the same as active ingredients
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
CA2290509A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
AU2180500A (en) 1998-12-15 2000-07-03 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
PL348326A1 (en) 1998-12-22 2002-05-20 Warner Lambert Co Combination chemotherapy
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
EP1150950A2 (en) 1999-01-13 2001-11-07 Warner-Lambert Company Anthranilic acid derivatives
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
CA2355470C (en) 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
HUP0105092A3 (en) 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
JP2003504400A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
KR20030059115A (ko) * 2000-08-25 2003-07-07 워너-램버트 캄파니 엘엘씨 Ｎ-아릴-안트라닐산 및 그의 유도체의 제조 방법
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
CN1568184A (zh) 2001-10-31 2005-01-19 辉瑞产品公司 烟碱乙酰胆碱受体激动剂在治疗多动腿综合征中的用途
EP1467968A1 (en) 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1515727A4 (en) 2002-06-11 2009-04-08 Merck & Co Inc (HALO-BENZO CARBONYL) HETEROBICYCLIC P38 KINASE INHIBITION
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003248813A1 (en) 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
CA2517517C (en) 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EP1641804A1 (en) 2003-06-20 2006-04-05 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8084645B2 (en) 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2547804A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivatives
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
MX2007004781A (es) 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
HRP20110498T1 (hr) * 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
MA38085B1 (fr) 2012-10-12 2018-11-30 Exelixis Inc Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
JP6451652B2 (ja) 2014-02-07 2019-01-16 住友化学株式会社 （ｒ）−１，１，３−トリメチル−４−アミノインダンの製造方法
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
KR20150067339A (ko) 2015-06-17
HK1213878A1 (en) 2016-07-15
EA030613B1 (ru) 2018-08-31
JP2018052973A (ja) 2018-04-05
PE20200387A1 (es) 2020-02-24
AU2013328929B2 (en) 2018-01-04
CR20200237A (es) 2020-07-26
BR112015008113B1 (pt) 2022-05-24
EP2909188A1 (en) 2015-08-26
IL238116B (en) 2018-06-28
TR201807861T4 (tr) 2018-06-21
EA201590700A1 (ru) 2015-09-30
US10793541B2 (en) 2020-10-06
HRP20180670T1 (hr) 2018-07-13
US20150210668A1 (en) 2015-07-30
US9771347B2 (en) 2017-09-26
PH12015500785B1 (en) 2015-06-15
US10239858B2 (en) 2019-03-26
MX2015004660A (es) 2015-08-07
NZ706723A (en) 2018-07-27
CR20150245A (es) 2015-11-19
PE20191818A1 (es) 2019-12-27
PL2909188T3 (pl) 2018-08-31
BR112015008113A2 (pt) 2017-07-04
AU2013328929A1 (en) 2015-04-30
CN104837826B (zh) 2018-07-27
ES2671502T3 (es) 2018-06-06
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
CL2015000926A1 (es) 2015-08-28
MA38085A1 (fr) 2018-08-31
CA2889466C (en) 2021-09-14
CA2889466A1 (en) 2014-04-17
IN2015DN03928A (https=) 2015-10-02
MX2020005533A (es) 2020-10-12
PE20151494A1 (es) 2015-11-06
ZA201502349B (en) 2019-12-18
CN108948043B (zh) 2021-05-04
CN108948043A (zh) 2018-12-07
SA515360271B1 (ar) 2016-05-19
EP2909188B1 (en) 2018-03-07
UA115455C2 (uk) 2017-11-10
HK1213567A1 (zh) 2016-07-08
MX372708B (es) 2020-05-29
US11414396B2 (en) 2022-08-16
WO2014059422A1 (en) 2014-04-17
US20200392104A1 (en) 2020-12-17
CN104837826A (zh) 2015-08-12
SG11201502795VA (en) 2015-05-28
US20170349569A1 (en) 2017-12-07
SI2909188T1 (en) 2018-07-31
GEP201706690B (en) 2017-06-26
MY186549A (en) 2021-07-26
KR102204520B1 (ko) 2021-01-20
JP2015533175A (ja) 2015-11-19
PH12015500785A1 (en) 2015-06-15

Similar Documents

Publication Publication Date Title
JP6300042B2 (ja) 癌の処置に使用するための化合物の製造方法
JP6494624B2 (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
CN107089985B (zh) 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物
CN113557235A (zh) 用于药物治疗的杂环化合物
EP3126349B1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
CN121843945A (zh) 具有抗kras突变肿瘤活性的化合物
CN103702998A (zh) 生产氮杂吲哚类的方法和中间体
TWI695831B (zh) Ｃｒｔｈ２拮抗劑化合物及其用途
WO2007058305A1 (ja) シンナミド誘導体の製造方法
AU2018208516B2 (en) Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
CA2943013A1 (en) Pyridine-2-amides useful as cb2 agonists
CA3085879A1 (en) Substituted pyrrolidine amides ii
KR20190062081A (ko) Jak 저해제 화합물, 및 이의 제조방법
WO2022107755A1 (ja) 新規アクリジニウム塩およびその製造方法
CN111517969A (zh) 地佐辛衍生物及其医药用途
CN103328471A (zh) 制备氮杂吲唑衍生物的方法
HK1213878B (en) Novel process for making compounds for use in the treatment of cancer
HK40064179A (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
TW201206901A (en) Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
WO2011002076A1 (ja) ラクタム化合物の製造方法およびその製造中間体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170719

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180126

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180214

R150 Certificate of patent or registration of utility model

Ref document number: 6300042

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250